Richard Weiten

6PUBLICATIONS
45CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 09, 2026
Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma.

|Oct 07, 2025
Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors.

Laurenz Sperber, Melanie von Brandenstein, Carolina Kessler

|Sep 01, 2025
TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy.

Carolina Kessler, Melanie von Brandenstein, Niklas Klümper

|Dec 20, 2024
The New Tumour Biomarker miRNA-371-3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines.

Richard Weiten, Theadora Engler, Hubert Schorle

|Jul 29, 2024
Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer.

Richard Weiten, Marit Bernhardt, Max Niemann

|Jun 19, 2024
Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer.

Richard Weiten, Max Niemann, Eduard Below

Pageof 1

Frequent Collaborators

1 joint publications

Johannes Siewert

1 joint publications

Jörg Ellinger

1 joint publications

Daniel Nettersheim

1 joint publications

Niklas Klümper